Beverly G. Tchang, MD (@BevTchangMD) / X

Beverly G. Tchang, MD

6,428 posts

Beverly G. Tchang, MD

@BevTchangMD

#Endocrinologist. Passionate about #obesity as a medical disease and a social misunderstanding. Tweets are my own. | #health #medtwitter #weightloss #medicine |

New York, NY

Joined June 2017

Pinned
Beverly G. Tchang, MD
@BevTchangMD
Oct 8, 2025
Thankful to @JAMA_current for sharing my #Viewpoint on Primordial Care 👉jamanetwork.com/journals/jama/… I've spent a long time wondering about where my patients are and who is taking care of those who are not my patients, especially when trust in medical and #publichealth institutions
Beverly G. Tchang, MD
@BevTchangMD
Aug 15, 2025
I'm coining a new term: primordial care. ⭐️Primordial care is the stage when a person is actively engaging with their #health before their first contact with the #healthcare system. ⭐️ It is the individual-level equivalent of #publichealth primordial prevention. Primordial
6K
Beverly G. Tchang, MD
@BevTchangMD
Nov 4, 2024
Treatment of #obesity = End of type 2 #diabetes #OW2024 #tirzepatide
38K
Beverly G. Tchang, MD
@BevTchangMD
Feb 20, 2024
This is a beautiful study, answering many of the questions we clinicians and our patients are asking: 🤔What happens if I stop the GLP1? Here's one punch line that we all could've guessed: ⭐️Exercise mitigates #weight regain when anti #obesity #medicine is stopped⭐️ But
Dimitris Papamargaritis
@ri_tis
Feb 20, 2024
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial thelancet.com/journals/eclin… @MichaelMindrum @MichaelAlbertMD @Grannell_
117K
Beverly G. Tchang, MD
@BevTchangMD
Aug 8, 2023
‼️Our long awaited SELECT trial results 👉 RCT adults w/ #obesity/overweight + #CVD on semaglutide 2.4 #Wegovy vs placebo x ~4 yrs 👏 ⬇️20% incidence of CVD death, nonfatal MI, nonfatal stroke 👉1st GLP1 to prove ⬇️ CVD in ppl w/o #T2DM novonordisk.com/content/nncorp… #CardioTwitter
60K
Beverly G. Tchang, MD
@BevTchangMD
Aug 24, 2022
Consider this: #weightloss is NOT the treatment for #obesity Weight loss is the RESULT of treating obesity Lifestyle changes, medications, and/or surgery re-wire the homeostatic and hedonic feeding circuits in your brain, which characterize the pathophysiology of obesity
Beverly G. Tchang, MD
@BevTchangMD
Mar 15, 2023
🔥tip: GLP1s can affect absorption of other #medications eg) Rybelsus ↑ levothyroxine absorption by 33% If your patient is experiencing new side effects that you can't attribute directly to the GLP1, they might be absorbing more of their other medications #medicine #endocrine
23K
Beverly G. Tchang, MD
@BevTchangMD
Jan 31, 2023
Lots of concern about #weight regain after stopping a med like #ozempic people.com/health/ozempic… Great study cited by @people : dom-pubs.onlinelibrary.wiley.com/doi/10.1111/do… shows what happened in STEP1 extension Weight seems to go back to baseline. But not worse. There’s no excess rebound effect.
50K
Beverly G. Tchang, MD
@BevTchangMD
Jun 26, 2023
@AniaJastreboff on @EliLillyandCo 's retatrutide data for #obesity Just gonna let this sit here ⭐️24% #weightloss at just 48 wks ⭐️💯% with clinically significant #weightloss #ADARME #ADA2023
97K
Beverly G. Tchang, MD
@BevTchangMD
Apr 2, 2025
Looking forward to 2025-2027 outcome studies of #tirzepatide for #obesity related consequences in various populations @EliLillyandCo Ref: tandfonline.com/doi/pdf/10.108…
10K
Beverly G. Tchang, MD
@BevTchangMD
Oct 13, 2023
Looking for an intro on the State of #Obesity #Medicine? Check out my @WeillCornell Medicine Grand Rounds drive.google.com/file/d/10tKQwx… I discuss: 👉What makes obesity a disease? 👉How do genetics and environment cause obesity? 👉How do we use on- and off-label anti obesity
26K
Beverly G. Tchang, MD
@BevTchangMD
Jul 1, 2023
Ready for a deep dive into #retatrutide from @EliLillyandCo @AniaJastreboff ? You can bet I was excited to see 43 pages of supplemental appendix... nejm.org/doi/full/10.10… 🧵 1/ #obesity #endocrinology #endocrine #research
nejm.org
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effe...
33K
Beverly G. Tchang, MD
@BevTchangMD
Jan 3, 2025
Two observational studies find the same bottom line: #Ozempic may be linked to NAION = non arteritic anterior ischemic optic neuropathy The risk? 1 in 10,000 health.com/ozempic-vision… @health_com_ 👉 This data has not changed my clinical practice
Health News and Trending Stories
From health.com
16K
Beverly G. Tchang, MD
@BevTchangMD
Jul 17, 2023
July means my new fellows are learning about the foundations of #obesity management I'm starting didactics with the physiology of energy regulation and pathophysiology of obesity This is a great primer if anyone wants some reading on this topic: nature.com/articles/nrdp2…
15K
Beverly G. Tchang, MD
@BevTchangMD
Oct 4, 2023
#Ozempic Is Making People Buy Less Food, Walmart Says finance.yahoo.com/news/ozempic-c…
76K